HK1250950A1 - 曲美他嗪在製備防治肝病的藥物中的用途 - Google Patents
曲美他嗪在製備防治肝病的藥物中的用途Info
- Publication number
- HK1250950A1 HK1250950A1 HK18110483.3A HK18110483A HK1250950A1 HK 1250950 A1 HK1250950 A1 HK 1250950A1 HK 18110483 A HK18110483 A HK 18110483A HK 1250950 A1 HK1250950 A1 HK 1250950A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- trimethazine
- drugs
- preventing
- preparation
- liver diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510207528.0A CN104840462A (zh) | 2015-04-28 | 2015-04-28 | 曲美他嗪在防治肝病中的具有作为护肝药物的新用途 |
| PCT/CN2016/080219 WO2016173486A1 (zh) | 2015-04-28 | 2016-04-26 | 曲美他嗪在制备防治肝病的药物中的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1250950A1 true HK1250950A1 (zh) | 2019-01-18 |
Family
ID=53840712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18110483.3A HK1250950A1 (zh) | 2015-04-28 | 2018-08-15 | 曲美他嗪在製備防治肝病的藥物中的用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180153886A1 (zh) |
| EP (1) | EP3290034A4 (zh) |
| JP (2) | JP2018514556A (zh) |
| CN (2) | CN104840462A (zh) |
| CA (1) | CA3012165A1 (zh) |
| HK (1) | HK1250950A1 (zh) |
| MA (1) | MA41996A (zh) |
| WO (1) | WO2016173486A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104840462A (zh) * | 2015-04-28 | 2015-08-19 | 余祖江 | 曲美他嗪在防治肝病中的具有作为护肝药物的新用途 |
| CN105287564A (zh) * | 2015-09-06 | 2016-02-03 | 余祖江 | 一种防治肝病的西药复合物及其用途 |
| US11077105B2 (en) | 2016-11-15 | 2021-08-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Therapy for mitochondrial fatty acid beta-oxidation and transport disorders |
| EP3755329A4 (en) * | 2018-02-19 | 2021-10-27 | Martin Pharmaceuticals, Inc. | STABLE LIQUID FORMULATION OF TRIMETAZIDINE FOR ORAL USE |
| WO2019161308A1 (en) * | 2018-02-19 | 2019-08-22 | Martin Pharmaceuticals Inc. | Use of anti-ischemic compounds in treating acute-on-chronic liver failure |
| US20190381034A1 (en) * | 2018-06-14 | 2019-12-19 | Ming Fang | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases |
| CN108619152A (zh) * | 2018-06-27 | 2018-10-09 | 余祖江 | 曲美他嗪作为免疫抑制剂在治疗免疫相关疾病中的应用 |
| CN109010342A (zh) * | 2018-07-05 | 2018-12-18 | 方明 | 用于慢加急性肝衰竭及相关肝病的药物组合物和方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1865945A4 (en) * | 2005-03-11 | 2008-05-21 | Hong Kong Nitric Oxide Ltd | TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES |
| CN102058888B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种治疗能量代谢异常的药物组合物和其应用 |
| CN104840462A (zh) * | 2015-04-28 | 2015-08-19 | 余祖江 | 曲美他嗪在防治肝病中的具有作为护肝药物的新用途 |
-
2015
- 2015-04-28 CN CN201510207528.0A patent/CN104840462A/zh active Pending
-
2016
- 2016-04-26 JP JP2017556732A patent/JP2018514556A/ja not_active Withdrawn
- 2016-04-26 US US15/569,997 patent/US20180153886A1/en not_active Abandoned
- 2016-04-26 WO PCT/CN2016/080219 patent/WO2016173486A1/zh active Application Filing
- 2016-04-26 CA CA3012165A patent/CA3012165A1/en not_active Abandoned
- 2016-04-26 EP EP16785917.2A patent/EP3290034A4/en active Pending
- 2016-04-26 CN CN201680038116.1A patent/CN108025007A/zh active Pending
- 2016-04-26 MA MA041996A patent/MA41996A/fr unknown
- 2016-08-18 US US15/240,677 patent/US11020392B2/en active Active
-
2018
- 2018-08-15 HK HK18110483.3A patent/HK1250950A1/zh unknown
-
2021
- 2021-04-22 JP JP2021072840A patent/JP2021119162A/ja active Pending
- 2021-04-29 US US17/244,039 patent/US20210322407A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180153886A1 (en) | 2018-06-07 |
| JP2021119162A (ja) | 2021-08-12 |
| CA3012165A1 (en) | 2016-11-03 |
| CN104840462A (zh) | 2015-08-19 |
| US11020392B2 (en) | 2021-06-01 |
| EP3290034A4 (en) | 2018-11-07 |
| EP3290034A1 (en) | 2018-03-07 |
| MA41996A (fr) | 2018-03-07 |
| US20160354366A1 (en) | 2016-12-08 |
| WO2016173486A1 (zh) | 2016-11-03 |
| US20210322407A1 (en) | 2021-10-21 |
| CN108025007A (zh) | 2018-05-11 |
| JP2018514556A (ja) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285179A (en) | Pharmaceutical preparations containing synthetic glycans for use in the treatment of diseases of the digestive system and methods and methods for their preparation | |
| PL3386484T3 (pl) | Kompozycje i sposoby dostarczania środków terapeutycznych | |
| HK1250950A1 (zh) | 曲美他嗪在製備防治肝病的藥物中的用途 | |
| PT3031826T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro | |
| PL3487505T3 (pl) | Podawanie i dawkowanie diaminofenotiazyn | |
| IL257784A (en) | Methods and compositions for reducing fat | |
| IL265955A (en) | Therapeutic compounds and methods of use thereof | |
| IL254842B (en) | Therapeutic preparations and methods for use in cancer treatment | |
| FI3380525T3 (fi) | Lääkeformulaatioita ja niiden käyttömenetelmiä | |
| HK1257237A1 (zh) | 預防和治療脂肪肝的藥物及其用途 | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases | |
| HK1255689A1 (zh) | 三乙酰基-3-羥基苯基腺苷在製備預防或者治療非酒精性脂肪肝藥物中的應用 | |
| EP2962693A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CANCER | |
| HK1245644B (zh) | 投予特拉萬星的劑量和方法 | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| HK1258056A1 (zh) | 治療性化合物和其使用方法 | |
| HK1245094A1 (zh) | 一種治療抑鬱症的藥物組合物及其製備方法 | |
| PT3503885T (pt) | Composição farmacêutica e métodos de utilização | |
| IL249440B (en) | Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases | |
| IL249860A0 (en) | Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer | |
| GB201519644D0 (en) | Therapy and pharmaceutical composition | |
| IL257689B (en) | Pharmaceutical preparations and methods for treating diseases related to lack of oxygen | |
| IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases | |
| GB201612863D0 (en) | Administration and dosage of diaminophenothiazines |